08.02.19
Vetio has completed its Montreal plant expansion to accommodate commercial scale manufacturing of veterinary drug products for the North American, European and other global markets.
The facility produces liquids, semi-solids, tablets, intermediates and blends, such as its proprietary Flavorpal palatant system. Production capacity was also installed for pharmaceutical soft chews based on Vetio’s intellectual property. Vetio’s services begin with early-stage pre-formulation and product development, where it has extensive development capabilities at both the lab-scale and pilot-scale. Analytical services include method development, stability studies, and release testing.
“We have always provided manufacturing services for clinical trial materials and registration batches,” said John Kane, chief executive officer, Vetio. “Coupling this plant expansion with a team of project managers, Vetio is now well-equipped for commercial manufacturing, including technical transfers of finished veterinary drug products. It can be difficult to find both development partners and contract manufacturers that understand the unique requirements of veterinary drugs, so we decided to create the total solution as a CDMO dedicated to animal health.”
Vetio acquired Tetragenx Animal Health in March 2018, and in the last 12 months, Vetio has helped its customers achieve three FDA CVM Market Authorizations, received a Pre-Approval Inspection from the FDA with no observations, and completed the plant expansion to provide the Animal Health industry with more options for commercial manufacturing.
The facility produces liquids, semi-solids, tablets, intermediates and blends, such as its proprietary Flavorpal palatant system. Production capacity was also installed for pharmaceutical soft chews based on Vetio’s intellectual property. Vetio’s services begin with early-stage pre-formulation and product development, where it has extensive development capabilities at both the lab-scale and pilot-scale. Analytical services include method development, stability studies, and release testing.
“We have always provided manufacturing services for clinical trial materials and registration batches,” said John Kane, chief executive officer, Vetio. “Coupling this plant expansion with a team of project managers, Vetio is now well-equipped for commercial manufacturing, including technical transfers of finished veterinary drug products. It can be difficult to find both development partners and contract manufacturers that understand the unique requirements of veterinary drugs, so we decided to create the total solution as a CDMO dedicated to animal health.”
Vetio acquired Tetragenx Animal Health in March 2018, and in the last 12 months, Vetio has helped its customers achieve three FDA CVM Market Authorizations, received a Pre-Approval Inspection from the FDA with no observations, and completed the plant expansion to provide the Animal Health industry with more options for commercial manufacturing.
